Overview

The Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of HEC96719 Tablets in Healthy Subjects

Status:
Completed
Trial end date:
2021-02-23
Target enrollment:
Participant gender:
Summary
The Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Non-alcoholic fatty liver disease (NAFLD) treatment drug HEC96719 in Healthy Male and Female Subjects
Phase:
Phase 1
Details
Lead Sponsor:
Sunshine Lake Pharma Co., Ltd.